ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.93
+0.80 (+4.18%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.13
Open19.27
Bid0.00 x 800
Ask0.00 x 800
Day's Range19.00 - 20.04
52 Week Range17.68 - 44.00
Volume387,856
Avg. Volume531,435
Market Cap541.907M
Beta1.83
PE Ratio (TTM)N/A
EPS (TTM)-4.94
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.00
Trade prices are not sourced from all markets
  • A Financial Overview of Supernus Pharmaceuticals in September
    Market Realist13 days ago

    A Financial Overview of Supernus Pharmaceuticals in September

    In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.

  • Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
    Market Realist13 days ago

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.

  • GlobeNewswire13 days ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 68,251 shares of the company’s common stock, at a per share exercise price of $22.76, the closing trading price on September 10, 2018, and restricted stock units to acquire 11,373 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of Influence

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Adamas Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 44,016 shares of the company’s common stock, at a per share exercise price of $24.22, the closing trading price on August 7, 2018, and restricted stock units to acquire 7,334 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...

  • Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates

    Adamas (ADMS) delivered earnings and revenue surprises of 10.64% and 56.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Adamas: 2Q Earnings Snapshot

    On a per-share basis, the Emeryville, California-based company said it had a loss of $1.26. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Adamas Reports Second Quarter 2018 Financial Results

    -GOCOVRI™ extended release capsules product sales reached $7.6 million for the second quarter-. EMERYVILLE, Calif., Aug. 02, 2018-- Adamas Pharmaceuticals, Inc. today reported financial results and pipeline ...

  • ACCESSWIRE2 months ago

    Adamas Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...

  • GlobeNewswire2 months ago

    Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia

    Adamas Pharmaceuticals, Inc. (ADMS) today announced the launch of “Dyskinesia Is A Jerk,” an integrated disease education campaign focused on raising awareness about Parkinson’s disease (PD) dyskinesia and its impact, with an educational, supportive environment where people with PD dyskinesia and their care partners may share real-life experiences, have candid conversations, and unite as a community. In the United States, PD affects close to 1 million people, and of those, between 150,000 and 200,000 people experience dyskinesia, which is different from tremors (shaking in the hands and feet) and is characterized by sudden, jerky, and uncontrollable movements in the neck/face, arms, legs, torso, or entire body that can worsen over time.

  • GlobeNewswire2 months ago

    Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the company will report second quarter 2018 financial results on Thursday, August 2, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.

  • Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
    Market Realist2 months ago

    Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today

    Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.

  • GlobeNewswire3 months ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 29,531 shares of the company’s common stock, at a per share exercise price of $25.74, the closing trading price on July 9, 2018, and restricted stock units to acquire 4,921 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • ACCESSWIRE3 months ago

    Free Technical Research on Akorn and Three More Generic Drugs Equities

    WallStEquities.com has selected the following Generic Drugs stocks for review today: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), and Allergan PLC (NYSE: AGN). Companies in the generic pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse.

  • Why Axovant Sciences Stock Rose in Week Ended June 8
    Market Realist3 months ago

    Why Axovant Sciences Stock Rose in Week Ended June 8

    Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Adamas Pharmaceuticals Inc Earnings Call

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...